May 28, 2024:

Monika Joshi, MD, MRCP, has been re-appointed as the chief scientific officer of the Big Ten Cancer Research Consortium.

Dr. Joshi has served as the CSO of the Big Ten CRC since 2021, when she was first appointed, succeeding Ruth O’Regan, MD. She will serve another three-year term in this role.

“It has been a pleasure and honor to be part of the growing research community at Big Ten Cancer Research Consortium. I am very excited to continue the journey and collaborate with experts at our member institutions to move our field forward,” Dr. Joshi said.

Dr. Joshi is a Professor in the Division of Hematology-Oncology in Department of Medicine at Penn State College of Medicine. She is an Endowed Professor of Cancer Clinical Investigation at Penn State Cancer Institute. She serves as disease team co-leader for the genitourinary diseases group at Penn State Cancer Institute and as medical director for the Cancer Institute’s Clinical Trials Office.

Dr. Joshi has been active in the Big Ten CRC since the consortium’s founding. In addition to leading multiple Big Ten CRC studies, she has served on the Big Ten CRC Steering Committee and the Genitourinary Clinical Trial Working Group as a co-chair.

“We have seen growth in the consortium with the successful formation of new working groups such as AYA and Population Science,” Dr. Joshi stated. “I look forward to working with our team of administrators and researchers at Big Ten Cancer Research Consortium.”

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow. Since its founding, the Big Ten CRC has activated nearly 40 clinical trials across a wide range of cancer types, more than 1,000 participants have enrolled in Big Ten CRC studies, and more than 500 researchers have joined Big Ten CRC Clinical Trial Working Groups. 

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 14 Big Ten institutions will provide over $200 million in direct financial support to more than 9,800 students for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women, including the addition of men’s ice hockey and men’s and women’s lacrosse since 2013. For more information, visit www.bigten.org.